hydroxychloroquine plus macrolides - for COVID-19 mild to moderate method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.60 [0.14, 2.54]< 10%1 study (1 / -)75.7 %some concernnot evaluable moderatecrucial-
clinical worsening 0.99 [0.57, 1.72]< 10%1 study (1 / -)51.4 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

This meta-analysis covered 1 pathologies: 90 90